• PARP inhibitors may increase risk for myelodysplastic syndrome, AML

    2 days ago - By Healio

    Poly polymerase, or PARP, inhibitors appeared associated with increased risk for secondary myelodysplastic syndrome and acute myeloid leukemia compared with placebo among patients with cancer, according to study results.
    “These delayed and often lethal adverse events should be studied further to improve clinical understanding, particularly in the front-line maintenance setting,” Pierre-Marie Morice, PhD, researcher in the interdisciplinary research unit for cancer prevention and treatment at Normandie University in France, and colleagues wrote in the study, published in
    Read more ...